Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of the adminstration of celecoxib, a
cox2-inhibitor in patients with stage II-III non small cell lung cancer receiving radical
radiotherapy.
The hypothesis is that celecoxib will increase the remission rate of radiotherapy.